A collaboration between Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs has launched BrightSeq, a consortium dedicated to integrating clinical tissue and liquid biopsy sequencing for pediatric cancer patients. This initiative aims to enhance genomic profiling capabilities, improve rare cancer prognostic assessments, and accelerate precision medicine approaches in childhood cancers. The program promises to provide comprehensive multimodal diagnostics leveraging the combined expertise of leading institutions.